BR112022020814A2 - Métodos para tratamento de síndrome de liberação de citocina - Google Patents

Métodos para tratamento de síndrome de liberação de citocina

Info

Publication number
BR112022020814A2
BR112022020814A2 BR112022020814A BR112022020814A BR112022020814A2 BR 112022020814 A2 BR112022020814 A2 BR 112022020814A2 BR 112022020814 A BR112022020814 A BR 112022020814A BR 112022020814 A BR112022020814 A BR 112022020814A BR 112022020814 A2 BR112022020814 A2 BR 112022020814A2
Authority
BR
Brazil
Prior art keywords
cytokine release
treatment
methods
release syndrome
disease
Prior art date
Application number
BR112022020814A
Other languages
English (en)
Inventor
R Bray Mark
M Mason Jacqueline
Wei Xin
Duncan Gordon
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112022020814A2 publication Critical patent/BR112022020814A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

MÉTODO PARA TRATAMENTO DE SÍNDROME DE LIBERAÇÃO DE CITOCINA. A presente invenção refere-se a um método de tratamento de um indivíduo com liberação de citocina aberrante derivada de uma doença ou condição ou sob risco de desenvolver liberação de citocina aberrante derivada de uma doença ou condição. O método compreende administrar ao indivíduo uma quantidade eficaz de um composto representado pela fórmula estrutural (I) ou um sal farmaceuticamente aceitável do mesmo. As variáveis na fórmula estrutural (I) são como descritas no presente relatório.
BR112022020814A 2020-04-13 2021-04-12 Métodos para tratamento de síndrome de liberação de citocina BR112022020814A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009059P 2020-04-13 2020-04-13
US202063022956P 2020-05-11 2020-05-11
PCT/CA2021/050483 WO2021207828A1 (en) 2020-04-13 2021-04-12 Methods for treating cytokine release syndrome

Publications (1)

Publication Number Publication Date
BR112022020814A2 true BR112022020814A2 (pt) 2022-11-29

Family

ID=78083464

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020814A BR112022020814A2 (pt) 2020-04-13 2021-04-12 Métodos para tratamento de síndrome de liberação de citocina

Country Status (12)

Country Link
US (1) US20230144869A1 (pt)
EP (1) EP4135695A1 (pt)
JP (1) JP2023522618A (pt)
KR (1) KR20230018365A (pt)
CN (1) CN115867275A (pt)
AU (1) AU2021257439A1 (pt)
BR (1) BR112022020814A2 (pt)
CA (1) CA3175420A1 (pt)
IL (1) IL297314A (pt)
MX (1) MX2022012812A (pt)
TW (1) TW202203917A (pt)
WO (1) WO2021207828A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MA58653B1 (fr) * 2020-06-26 2024-02-29 Valenta Intellekt Ltd Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6
WO2023143384A1 (zh) * 2022-01-27 2023-08-03 四川海思科制药有限公司 一种抑制或降解hpk1激酶的化合物及其在医药中的用途
WO2023164503A2 (en) * 2022-02-22 2023-08-31 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006102191A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
LT3322711T (lt) * 2015-06-25 2021-05-10 University Health Network Hpk1 inhibitoriai ir jų panaudojimo būdai
CN109721620B (zh) * 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
AU2019413504A1 (en) * 2018-12-26 2021-06-03 Janssen Pharmaceutica Nv Thienopyridinone compounds

Also Published As

Publication number Publication date
TW202203917A (zh) 2022-02-01
KR20230018365A (ko) 2023-02-07
US20230144869A1 (en) 2023-05-11
EP4135695A1 (en) 2023-02-22
CN115867275A (zh) 2023-03-28
WO2021207828A1 (en) 2021-10-21
AU2021257439A1 (en) 2022-12-15
IL297314A (en) 2022-12-01
JP2023522618A (ja) 2023-05-31
MX2022012812A (es) 2023-01-30
CA3175420A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
BR112022020814A2 (pt) Métodos para tratamento de síndrome de liberação de citocina
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112018074027A2 (pt) tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmo
BR112022020291A2 (pt) Inibidores de cd38
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
EA202192433A1 (ru) Соединения, полезные в терапии вич
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
BR112022024156A2 (pt) Compostos heterocílicos antelmínticos
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
BR112022012737A2 (pt) Composto antagonista de pd-l1
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
BR112018002763A2 (pt) método para cicatrização de ferimentos
BR112020026014A8 (pt) Derivado de lactama condensado
MX2022011240A (es) Azálidos de urea inmunomoduladores.
BR112021024835A2 (pt) Tratamento para sinuclenopatias
PH12020551620A1 (en) Compositions for preventing or treating dry eye

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing